BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 30814111)

  • 1. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SS18-SSX drives CREB activation in synovial sarcoma.
    Cyra M; Schulte M; Berthold R; Heinst L; Jansen EP; Grünewald I; Elges S; Larsson O; Schliemann C; Steinestel K; Hafner S; Simmet T; Wardelmann E; Kailayangiri S; Rossig C; Isfort I; Trautmann M; Hartmann W
    Cell Oncol (Dordr); 2022 Jun; 45(3):399-413. PubMed ID: 35556229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
    Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
    Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
    Raquib AR; Hofvander J; Ta M; Nielsen TO
    Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
    Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
    Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
    Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
    Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.
    Törnkvist M; Natalishvili N; Xie Y; Girnita A; D'Arcy P; Brodin B; Axelson M; Girnita L
    Biochem Biophys Res Commun; 2008 Apr; 368(3):793-800. PubMed ID: 18267106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
    Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
    Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
    El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
    Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
    Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
    PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Wnt pathway in synovial sarcoma models.
    Barham W; Frump AL; Sherrill TP; Garcia CB; Saito-Diaz K; VanSaun MN; Fingleton B; Gleaves L; Orton D; Capecchi MR; Blackwell TS; Lee E; Yull F; Eid JE
    Cancer Discov; 2013 Nov; 3(11):1286-301. PubMed ID: 23921231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.
    Zaborowski M; Vargas AC; Pulvers J; Clarkson A; de Guzman D; Sioson L; Maclean F; Chou A; Gill AJ
    Histopathology; 2020 Oct; 77(4):588-600. PubMed ID: 32559341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.
    Lasota J; Chłopek M; Kaczorowski M; Natálie K; Ryś J; Kopczyński J; Sulaieva O; Michal M; Kruczak A; Harazin-Lechowska A; Szczepaniak M; Koshyk O; Hałoń A; Czapiewski P; Abdullaev Z; Kowalik A; Aldape KD; Michal M; Miettinen M
    Am J Surg Pathol; 2024 Jan; 48(1):97-105. PubMed ID: 37899499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
    McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
    Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
    Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
    PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
    Zöllner SK; Rössig C; Toretsky JA
    Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.